Jun 16, 2020
Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
May 29, 2020
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
May 06, 2020
Exact Sciences Announces First Quarter 2020 Results
Feb 11, 2020
Exact Sciences Announces Fourth-Quarter 2019 Results
Dec 12, 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
Nov 08, 2019
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
Oct 29, 2019
Exact Sciences reports third-quarter revenue growth of 85 percent to $219 million
Sep 30, 2019
New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Aug 21, 2019
New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
Jul 29, 2019
Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
Jun 03, 2019
Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
Jun 03, 2019
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer
May 29, 2019
Genomic Health to Present at the Jefferies 2019 Healthcare Conference
May 07, 2019
Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress
Mar 25, 2019
New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
Feb 21, 2019
Diagnostic Solutions Laboratory Revolutionizes Precision Medicine with GenomicInsight(TM) Genomic Health Profile Powered by Opus23 Explorer(TM)
Feb 20, 2019
Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
Feb 05, 2019
Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
Jan 07, 2019
Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Dec 19, 2018
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom